Kian Pee Wan Capsules Recalled Due to Undeclared Drug Ingredients

Key Takeaways:

• The US Food and Drug Administration (FDA) has issued a voluntary Class I recall for Kian Pee Wan capsules. The affected batches are all lots within expiration, containing 71 bottles.
• The recall was initiated by Buy-Herbal due to the presence of undeclared drugs dexamethasone and cyproheptadine, a quality issue that is likely to cause serious adverse health consequences or death.
• Kian Pee Wan capsules are used to improve appetite and weight gain.

The FDA has issued a Class I recall for Kian Pee Wan capsules, affecting 71 bottles. This product is being recalled by Buy-Herbal based in Flushing, New York. The recall was initiated on March 21, 2026, and received a Class I classification on August 17, 2026. A Class I classification means the use of this product is likely to cause serious adverse health consequences or death.

The recall was initiated due to the presence of undeclared drugs dexamethasone and cyproheptadine in the product. The medication was marketed without an approved New Drug Application (NDA) or Abbreviated NDA. This deficiency affects all lots within expiration. Buy-Herbal sent out a public notice via email; a press release was issued on March 13, 2026, and April 1, 2026.

Kian Pee Wan capsules are used as a dietary supplement to stimulate appetite and promote weight gain. Dexamethasone is used to treat inflammatory conditions and can impair the ability to fight infections. Cyproheptadine is used to treat seasonal allergies. Pharmacists should identify and quarantine the affected lots, remove them from inventory, and coordinate with prescribers to provide an alternative supply.

Reference

FDA. Enforcement Report. August 19, 2026. Accessed August 19, 2026. https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=219338